Nanofabrication Core Facility Nemucore Medical Innovations (NMI) is establishing a first in the nation cGLP nanomedicine manufacturing facility compliant with Quality by Design (QbD) principles. NMI activities will focus on converting consortium nanomedicines into target product profiles and defining the critical quality attributes required to manufacture material at a GLP scale. Our efforts will prove the NMI facility can become a national resource to advance the promise of nanomedicine. Fundamentally, NMI will be creating an environment where lab scale fabrication and chemistry will be engineered into repeatable, in control processes: a capability completely absent today. QbD allows a common manufacturing footprint to become a highly flexible process driven environment that is capable of handling multiple product pathways. This concept of flexibility is important as nanomedicines have taken on many different physical properties but they do have similarities in how they are assembled and prepared for investigational purposes. Additionally, the QdD model is also adaptable to multifunctional nanomedicines, with potential to target, image, and deliver therapeutic payload from a single platform. NMI's plan is use the core funding develop a QbD environment which can manufacturer multifunctional: liposomes, polymeric nanoparticles, liposomes, polymeric micelles, polymeric nanoparticles, and dendrimers. NMI's activities indicate how NMI will commission, calibrate, qualify, and validate a flexible manufacturing environment for the pilot scale GLP production ofthe consortiums nanomedicines.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Specialized Center--Cooperative Agreements (U54)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Northeastern University
United States
Zip Code
Jhaveri, Aditi; Deshpande, Pranali; Pattni, Bhushan et al. (2018) Transferrin-targeted, resveratrol-loaded liposomes for the treatment of glioblastoma. J Control Release 277:89-101
Wang, Tao; Narayanaswamy, Radhika; Ren, Huilan et al. (2018) Phage-derived protein-mediated targeted chemotherapy of pancreatic cancer. J Drug Target 26:505-515
Kumar, Gaurav; Goldberg, S Nahum; Gourevitch, Svetlana et al. (2018) Targeting STAT3 to Suppress Systemic Pro-Oncogenic Effects from Hepatic Radiofrequency Ablation. Radiology 286:524-536
Upponi, Jaydev R; Jerajani, Kaushal; Nagesha, Dattatri K et al. (2018) Polymeric micelles: Theranostic co-delivery system for poorly water-soluble drugs and contrast agents. Biomaterials 170:26-36
Petrenko, Valery A; Gillespie, James W (2017) Paradigm shift in bacteriophage-mediated delivery of anticancer drugs: from targeted 'magic bullets' to self-navigated 'magic missiles'. Expert Opin Drug Deliv 14:373-384
van de Ven, Anne L; Tangutoori, Shifalika; Baldwin, Paige et al. (2017) Nanoformulation of Olaparib Amplifies PARP Inhibition and Sensitizes PTEN/TP53-Deficient Prostate Cancer to Radiation. Mol Cancer Ther 16:1279-1289
Pattni, Bhushan S; Jhaveri, Aditi; Dutta, Ivy et al. (2017) Targeting energy metabolism of cancer cells: Combined administration of NCL-240 and 2-DG. Int J Pharm 532:149-156
Perche, Federico; Biswas, Swati; Patel, Niravkumar R et al. (2016) Hypoxia-Responsive Copolymer for siRNA Delivery. Methods Mol Biol 1372:139-62
Velez, Erik; Goldberg, S Nahum; Kumar, Gaurav et al. (2016) Hepatic Thermal Ablation: Effect of Device and Heating Parameters on Local Tissue Reactions and Distant Tumor Growth. Radiology 281:782-792
Zhang, Yilin; Sriraman, Shravan Kumar; Kenny, Hilary A et al. (2016) Reversal of Chemoresistance in Ovarian Cancer by Co-Delivery of a P-Glycoprotein Inhibitor and Paclitaxel in a Liposomal Platform. Mol Cancer Ther 15:2282-2293

Showing the most recent 10 out of 86 publications